InvestorsHub Logo
Post# of 252337
Next 10
Followers 1
Posts 39
Boards Moderated 0
Alias Born 09/15/2014

Re: None

Tuesday, 07/14/2015 1:40:24 PM

Tuesday, July 14, 2015 1:40:24 PM

Post# of 252337
NantKwest (previously Conkwest) in their amended S-1 doubled the number of shares being offered in their IPO from 100mil to 200mil. Think that is an indication of strong demand to a company controlled by Patrick Soon-Shiong?

Celgene backing Soon-Shiong's cancer biotech IPO, now dubbed NantKwest


July 14, 2015 | By John Carroll


Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created. In an amended IPO filing ConkWest is now named NantKwest, which will look to trade under the "NK" symbol on Nasdaq. And Soon-Shiong is bringing some close associates in on the deal, with Celgene (which acquired Abraxis from Soon-Shiong for $3 billion) agreeing to buy $17 million worth of shares on the debut and funds at Franklin Templeton committing to a $45 million buy. For the record, the little immuno-oncology player had spent about $46 million by the time Soon-Shiong stepped in earlier this year, raised cash for the company and pointed it to the public market in record time. Filing

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.